

Fengmin Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/726748/publications.pdf>

Version: 2024-02-01

142
papers

5,445
citations

101543

36
h-index

98798

67
g-index

144
all docs

144
docs citations

144
times ranked

8084
citing authors

#	ARTICLE	IF	CITATIONS
1	A global survey of alternative splicing of HBV transcriptome using long-read sequencing. <i>Journal of Hepatology</i> , 2022, 76, 234-236.	3.7	5
2	Relationship between the Level of Serum Golgi Protein 73 and the Risk of Short-term Death in Patients with ALD-ACLF. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	1.4	2
3	Diagnostic Value of Serum Golgi Protein 73 for Liver Inflammation in Patients with Autoimmune Hepatitis and Primary Biliary Cholangitis. <i>Disease Markers</i> , 2022, 2022, 1-7.	1.3	3
4	E2F1-mediated AUF1 upregulation promotes HCC development and enhances drug resistance via stabilization of AKR1B10. <i>Cancer Science</i> , 2022, 113, 1154-1167.	3.9	26
5	MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer. <i>Cell Death and Disease</i> , 2022, 13, 13.	6.3	27
6	Active HBV replication in hypoxic pericentral zone 3 is up-regulated by multiple host factors including HIF-1 α . <i>Journal of Hepatology</i> , 2022, , .	3.7	3
7	Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2022, 29, 420-431.	2.0	6
8	Characterization and distribution of HIV-infected cells in semen. <i>Emerging Microbes and Infections</i> , 2022, 11, 860-872.	6.5	0
9	High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection. <i>Antiviral Research</i> , 2022, 199, 105274.	4.1	9
10	SOX6-MAP4K4 pathway induces autophagy and contributes to the reduced chemosensitivity of cervical cancer. , 2022, 1, 34-37.		0
11	A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. <i>Emerging Microbes and Infections</i> , 2022, 11, 775-785.	6.5	7
12	<i>lncCDCA3L</i> inhibits cell proliferation via a novel <i>RNA</i> structure-based crosstalk with <i>CDCA3</i> in hepatocellular carcinoma. <i>Liver International</i> , 2022, 42, 1432-1446.	3.9	4
13	Immunocompromised rabbit model of chronic HEV reveals liver fibrosis and distinct efficacy of different vaccination strategies. <i>Hepatology</i> , 2022, 76, 788-802.	7.3	21
14	Letter to the editor: HBeAg expression suppressing/abolishing mutation elevated HBV DNA level in HBeAg-negative patients with chronic HBV infection. <i>Hepatology</i> , 2022, 76, E69-E70.	7.3	2
15	Solely HBsAg intrauterine exposure accelerates HBV clearance by promoting HBs-specific immune response in the mouse pups. <i>Emerging Microbes and Infections</i> , 2022, 11, 1356-1370.	6.5	1
16	Severe acute hepatitis in children with unknown aetiology, etiology analysis and the next action. <i>Virologica Sinica</i> , 2022, 37, 778-782.	3.0	4
17	Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?. <i>Hepatology</i> , 2021, 73, 2075-2076.	7.3	1
18	Deletion of Golgi protein 73 delayed hepatocyte proliferation of mouse in the early stages of liver regeneration. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1346-1356.	2.8	3

#	ARTICLE	IF	CITATIONS
19	Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy. <i>Journal of Viral Hepatitis</i> , 2021, 28, 20-29.	2.0	7
20	Cell Cycle Arrest Protein CDKN2C Is Not an HBV Host Factor. <i>Virologica Sinica</i> , 2021, 36, 810-813.	3.0	2
21	NFATc3 inhibits hepatocarcinogenesis and HBV replication via positively regulating RIG-I-mediated interferon transcription. <i>Oncolmunology</i> , 2021, 10, 1869388.	4.6	11
22	Deoxycholic Acid Upregulates Serum Golgi Protein 73 through Activating NF- κ B Pathway and Destroying Golgi Structure in Liver Disease. <i>Biomolecules</i> , 2021, 11, 205.	4.0	9
23	Neonatal hepatitis B vaccination protects mature adults from occult virus infection. <i>Hepatology International</i> , 2021, 15, 328-337.	4.2	6
24	Letter to the Editor: The Differences Between the Reverse Transcriptional Efficiency of HBV Pregenomic RNA and Transcriptional Efficiency of HBV Covalently Closed Circular DNA. <i>Hepatology</i> , 2021, 74, 1720-1721.	7.3	3
25	Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF. <i>Journal of Hepatology</i> , 2021, 75, 243-245.	3.7	4
26	NEK7 Promotes Pancreatic Cancer Progression And Its Expression Is Correlated With Poor Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 705797.	2.8	13
27	Pacbio Sequencing of PLC/PRF/5 Cell Line and Clearance of HBV Integration Through CRISPR/Cas-9 System. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 676957.	3.5	6
28	Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis. <i>PLoS Pathogens</i> , 2021, 17, e1010057.	4.7	10
29	Hepatitis B Virus Virions Produced Under Nucleos(t)ide Analogue Treatment Are Mainly Not Infectious Because of Irreversible DNA Chain Termination. <i>Hepatology</i> , 2020, 71, 463-476.	7.3	24
30	Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucleos(t)ide Analogue Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 719-727.e7.	4.4	72
31	<i>Helicobacter pylori</i> inhibits GKN1 expression via the CagA/p-ERK/AUF1 pathway. <i>Helicobacter</i> , 2020, 25, e12665.	3.5	17
32	Transient Chimeric Ad5/37 Fiber Enhances NK-92 Carrier Cell-Mediated Delivery of Oncolytic Adenovirus Type 5 to Tumor Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 376-389.	4.1	13
33	Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. <i>International Journal of Infectious Diseases</i> , 2020, 99, 171-178.	3.3	13
34	Is the life-long entecavir treatment really inevitable in chronic hepatitis B patients?. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1509-1510.	2.0	0
35	Yin-Yang 1 and HBx protein activate HBV transcription by mediating the spatial interaction of cccDNA minichromosome with cellular chromosome 19p13.11. <i>Emerging Microbes and Infections</i> , 2020, 9, 2455-2464.	6.5	18
36	Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2582-2591.e6.	4.4	57

#	ARTICLE	IF	CITATIONS
37	Junceollolide B, a novel inhibitor of Hepatitis B virus. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115603.	3.0	8
38	The Influence of Different Types of Serum Cholesterol on the Prognosis of Hepatitis B Virus-Related Hepatocellular Patients Needs More Attention. <i>Gastroenterology</i> , 2020, 159, 1190-1191.	1.3	0
39	Reply to: Correspondence relating to "SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19". <i>Journal of Hepatology</i> , 2020, 73, 996-998.	3.7	14
40	Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. <i>Disease Markers</i> , 2020, 2020, 1-7.	1.3	10
41	Sex-determining region Y box 4 (SOX4) suppresses Hepatitis B virus replication by inhibiting hepatocyte nuclear factor 4 κ B expression. <i>Antiviral Research</i> , 2020, 176, 104745.	4.1	5
42	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001174.	2.8	21
43	HBV Genome and Life Cycle. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1179, 17-37.	1.6	21
44	SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. <i>Journal of Hepatology</i> , 2020, 73, 807-816.	3.7	488
45	Monitoring of Serum HBV RNA, HBcrAg, HBsAg and anti-HBc Levels in Patients during Long-Term Nucleoside/Nucleotide Analogue Therapy. <i>Antiviral Therapy</i> , 2019, 24, 105-115.	1.0	35
46	Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein. <i>Small</i> , 2019, 15, e1902686.	10.0	58
47	Gene Editing: Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein (<i>Small</i> 38/2019). <i>Small</i> , 2019, 15, 1970205.	10.0	7
48	Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. <i>Disease Markers</i> , 2019, 2019, 1-10.	1.3	10
49	Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. <i>Journal of Gastroenterology</i> , 2019, 54, 1096-1105.	5.1	11
50	Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection. <i>Emerging Microbes and Infections</i> , 2019, 8, 879-894.	6.5	37
51	Long-term functional maintenance of primary human hepatocytes in vitro. <i>Science</i> , 2019, 364, 399-402.	12.6	147
52	Elevated apolipoprotein B predicts poor postsurgery prognosis in patients with hepatocellular carcinoma. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1957-1964.	2.0	18
53	Serum GP73 combined AST and GGT reflects moderate to severe liver inflammation in chronic hepatitis B. <i>Clinica Chimica Acta</i> , 2019, 493, 92-97.	1.1	18
54	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	8.1	342

#	ARTICLE	IF	CITATIONS
55	HBV T1719G mutation reduced HBV replication through mutant Enh II and HB x protein in vitro. Journal of Viral Hepatitis, 2019, 26, 710-717.	2.0	5
56	Over-gap PCR amplification to identify presence of replication-competent HBV DNA from integrated HBV DNA: An updated occult HBV infection definition. Journal of Hepatology, 2019, 70, 557-559.	3.7	10
57	Identification of <i>TAF1</i> , <i>HNF4A</i> , and <i>CALM2</i> as potential therapeutic target genes for liver fibrosis. Journal of Cellular Physiology, 2019, 234, 9045-9051.	4.1	24
58	Hepatocellular Carcinoma Surveillance and Treatment: A Way to Reduce Cancer-related Mortality in Cirrhotic Patients. Journal of Clinical and Translational Hepatology, 2019, 7, 1-2.	1.4	17
59	Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study. Journal of Clinical and Translational Hepatology, 2019, 7, 1-9.	1.4	6
60	Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 289-296.	0.9	11
61	Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis. American Journal of Cancer Research, 2019, 9, 2730-2748.	1.4	5
62	<i>RFX</i> 1 participates in doxorubicin-induced hepatitis B virus reactivation. Cancer Medicine, 2018, 7, 2021-2033.	2.8	12
63	Integration of hepatitis B virus S gene impacts on hepatitis B surface antigen levels in patients with antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1389-1396.	2.8	24
64	The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 282-294.	6.5	36
65	Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naïve HBV-infected individuals. Journal of Clinical Virology, 2018, 99-100, 71-78.	3.1	63
66	HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient. Journal of Hepatology, 2018, 68, 847-849.	3.7	27
67	Serum Golgi protein 73 is a marker comparable to APRI for diagnosing significant fibrosis in children with liver disease. Scientific Reports, 2018, 8, 16730.	3.3	11
68	Diacylglycerol kinase β predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma. Experimental Cell Research, 2018, 373, 211-220.	2.6	17
69	Serum HBV RNA is a Potential Predictor of Hepatitis B Surface Antigen Reversion. Hepatology Communications, 2018, 2, 1168-1171.	4.3	8
70	Early Env-specific CTLs effectively suppress viral replication in SHIV controller macaques. Cellular Immunology, 2018, 331, 30-37.	3.0	4
71	Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e352-e358.	1.1	19
72	Integration of Prealbumin into Child-Pugh Classification Improves Prognosis Predicting Accuracy in HCC Patients Considering Curative Surgery. Journal of Clinical and Translational Hepatology, 2018, 6, 1-8.	1.4	9

#	ARTICLE	IF	CITATIONS
73	Long-distance interaction of the integrated HPV fragment with MYC gene and 8q24.22 region upregulating the allele-specific MYC expression in HeLa cells. <i>International Journal of Cancer</i> , 2017, 141, 540-548.	5.1	36
74	Complete genome sequencing and clinical analysis of intrahepatic hepatitis B virus cccDNA from HCC. <i>Microbial Pathogenesis</i> , 2017, 109, 49-55.	2.9	7
75	CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice. <i>Scientific Reports</i> , 2017, 7, 2796.	3.3	44
76	PCDH9 acts as a tumor suppressor inducing tumor cell arrest at G0/G1 phase and is frequently methylated in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2017, 16, 4475-4482.	2.4	21
77	Reply to: "Serum HBV pgRNA as a clinical marker for cccDNA activity". <i>Journal of Hepatology</i> , 2017, 66, 462-463.	3.7	39
78	Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. <i>Frontiers of Medicine</i> , 2017, 11, 502-508.	3.4	26
79	Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). <i>Journal of Clinical and Translational Hepatology</i> , 2017, 5, 297-318.	1.4	181
80	The gRNA-miRNA-gRNA Ternary Cassette Combining CRISPR/Cas9 with RNAi Approach Strongly Inhibits Hepatitis B Virus Replication. <i>Theranostics</i> , 2017, 7, 3090-3105.	10.0	39
81	Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 16498-16506.	1.8	35
82	Down-regulation of NTCP expression by cyclin D1 in hepatitis B virus-related hepatocellular carcinoma has clinical significance. <i>Oncotarget</i> , 2017, 8, 56041-56050.	1.8	20
83	CCR6 B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis. <i>American Journal of Cancer Research</i> , 2017, 7, 1151-1163.	1.4	12
84	Prognostic value of p53 mutation for poor outcome of Asian primary liver cancer patients: evidence from a cohort study and meta-analysis of 988 patients. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7425-7433.	2.0	11
85	Decreased Expression of BNC1 and BNC2 Is Associated with Genetic or Epigenetic Regulation in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 153.	4.1	14
86	Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. <i>Scientific Reports</i> , 2016, 6, 19423.	3.3	42
87	Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell. <i>Molecular Carcinogenesis</i> , 2016, 55, 732-742.	2.7	42
88	Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 117-123.	1.8	2
89	Dysregulation of host cellular genes targeted by human papillomavirus (HPV) integration contributes to HPV-related cervical carcinogenesis. <i>International Journal of Cancer</i> , 2016, 138, 1163-1174.	5.1	54
90	Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 2293-2299.	1.8	4

#	ARTICLE	IF	CITATIONS
91	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. <i>Journal of Hepatology</i> , 2016, 65, 700-710.	3.7	331
92	Failure recovery of circulating NKG2D ⁺ CD56 ^{dim} NK cells in HBV-associated hepatocellular carcinoma after hepatectomy predicts early recurrence. <i>Oncolmmunology</i> , 2016, 5, e1048061.	4.6	16
93	Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. <i>Gut</i> , 2016, 65, 313-320.	12.1	112
94	Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 3702-3708.	1.8	49
95	Increased glyceraldehyde-3-phosphate dehydrogenase expression indicates higher survival rates in male patients with hepatitis B virus-associated hepatocellular carcinoma and cirrhosis. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1597-1604.	1.8	2
96	Alpha fetoprotein mediates HBx induced carcinogenesis in the hepatocyte cytoplasm. <i>International Journal of Cancer</i> , 2015, 137, 1818-1829.	5.1	42
97	Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. <i>International Journal of Medical Sciences</i> , 2015, 12, 416-422.	2.5	4
98	Hepatitis B Virus X Protein Stabilizes Cyclin D1 and Increases Cyclin D1 Nuclear Accumulation through ERK-Mediated Inactivation of GSK-3 β . <i>Cancer Prevention Research</i> , 2015, 8, 455-463.	1.5	20
99	Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population. <i>Tumor Biology</i> , 2015, 36, 6891-6900.	1.8	6
100	Reduced Red Blood Cell Count Predicts Poor Survival After Surgery in Patients With Primary Liver Cancer. <i>Medicine (United States)</i> , 2015, 94, e577.	1.0	23
101	DNA methylation consistency implicates the primary tumor cell origin of recurrent hepatocellular carcinoma. <i>Epigenomics</i> , 2015, 7, 581-592.	2.1	16
102	CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression. <i>Oncotarget</i> , 2015, 6, 4733-4744.	1.8	22
103	Comprehensive profiling of novel microRNA-9 targets and a tumor suppressor role of microRNA-9 via targeting IGF2BP1 in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 42040-42052.	1.8	54
104	Phenotype and function of CXCR5 ⁺ CD45RA ^{hi} CD4 ⁺ T cells were altered in HBV-related hepatocellular carcinoma and elevated serum CXCL13 predicted better prognosis. <i>Oncotarget</i> , 2015, 6, 44239-44253.	1.8	27
105	Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. <i>World Journal of Gastroenterology</i> , 2015, 21, 9554.	3.3	96
106	Analysis of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA and Serum Viral Markers in Treatment-Naive Patients with Acute and Chronic HBV Infection. <i>PLoS ONE</i> , 2014, 9, e89046.	2.5	31
107	Effectiveness of HCV core antigen and RNA quantification in HCV-infected and HCV/HIV-1-coinfected patients. <i>BMC Infectious Diseases</i> , 2014, 14, 577.	2.9	7
108	An unbalanced PD-L1/CD86 ratio in CD14 ⁺⁺ CD16 ⁺ monocytes is correlated with HCV viremia during chronic HCV infection. <i>Cellular and Molecular Immunology</i> , 2014, 11, 294-304.	10.5	20

#	ARTICLE	IF	CITATIONS
109	Protocadherin 9 inhibits epithelialâ€”mesenchymal transition and cell migration through activating GSK-3Î² in hepatocellular carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2014, 452, 567-574.	2.1	42
110	The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 60, 975-984.	3.7	95
111	Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. <i>Vaccine</i> , 2014, 32, 5316-5322.	3.8	36
112	Alternative splicing variants of human Fbx4 disturb cyclin D1 proteolysis in human cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 447, 158-164.	2.1	15
113	Coinfection with HIV-1 Alleviates Iron Accumulation in Patients with Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2014, 9, e98039.	2.5	8
114	Extensive Recombination Due to Heteroduplexes Generates Large Amounts of Artificial Gene Fragments during PCR. <i>PLoS ONE</i> , 2014, 9, e106658.	2.5	23
115	Methylationâ€”mediated repression of microRNA-129 enhances oncogenic SOX4 expression in HCC. <i>Liver International</i> , 2013, 33, 476-486.	3.9	62
116	Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma. <i>Journal of Medical Virology</i> , 2013, 85, 219-227.	5.0	30
117	The involvement of <i>Helicobacter pylori</i> thioredoxin-1 in gastric carcinogenesis. <i>Journal of Medical Microbiology</i> , 2013, 62, 1226-1234.	1.8	17
118	Selection of reference genes for RT-qPCR analysis in tumor tissues from male hepatocellular carcinoma patients with hepatitis B infection and cirrhosis. <i>Cancer Biomarkers</i> , 2013, 13, 345-349.	1.7	16
119	Development and Evaluation of a Pseudovirus-Luciferase Assay for Rapid and Quantitative Detection of Neutralizing Antibodies against Enterovirus 71. <i>PLoS ONE</i> , 2013, 8, e64116.	2.5	25
120	Quantitative methylation analysis reveals gender and age differences in p16 ^{INK4a} hypermethylation in hepatitis B virus-related hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 420-428.	3.9	44
121	AKR1B10 overexpression in breast cancer: Association with tumor size, lymph node metastasis and patient survival and its potential as a novel serum marker. <i>International Journal of Cancer</i> , 2012, 131, E862-71.	5.1	102
122	Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 57, 322-329.	3.7	50
123	Re-evaluation of the Carcinogenic Significance of Hepatitis B Virus Integration in Hepatocarcinogenesis. <i>PLoS ONE</i> , 2012, 7, e40363.	2.5	59
124	Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. <i>Cancer</i> , 2012, 118, 2431-2442.	4.1	104
125	Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. <i>Archives of Virology</i> , 2012, 157, 37-41.	2.1	44
126	Association of TNF-Î± Genetic Polymorphisms with Hepatocellular Carcinoma Susceptibility: A Case-Control Study in a Han Chinese Population. <i>International Journal of Biological Markers</i> , 2011, 26, 181-187.	1.8	22

#	ARTICLE	IF	CITATIONS
127	Impaired nuclear export of tumor-derived c-terminal truncated cyclin D1 mutant in ESCC cancer. <i>Oncology Letters</i> , 2011, 2, 1203-1211.	1.8	4
128	A Higher Correlation of HCV Core Antigen with CD4+ T Cell Counts Compared with HCV RNA in HCV/HIV-1 Coinfected Patients. <i>PLoS ONE</i> , 2011, 6, e23550.	2.5	10
129	Increased PD-1 expression and PD-1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection. <i>Journal of Medical Virology</i> , 2010, 82, 1152-1159.	5.0	35
130	Association between epidermal growth factor 61A/G polymorphism and hepatocellular carcinoma susceptibility in Chinese patients. <i>Liver International</i> , 2010, 30, 112-118.	3.9	30
131	A role of functional T-type Ca ²⁺ channel in hepatocellular carcinoma cell proliferation. <i>Oncology Reports</i> , 2009, 22, 1229-35.	2.6	22
132	No Association between EGF +61 A/G Polymorphism and Increased Risk of Glioma. <i>International Journal of Biological Markers</i> , 2009, 24, 77-82.	1.8	12
133	Synthesis and characterization of chitosan-based hydrogels. <i>International Journal of Biological Macromolecules</i> , 2009, 44, 121-127.	7.5	64
134	In Situ Mineralization of Hydroxyapatite on Electrospun Chitosan-Based Nanofibrous Scaffolds. <i>Macromolecular Bioscience</i> , 2008, 8, 239-246.	4.1	84
135	Mutations in Fbx4 Inhibit Dimerization of the SCFFbx4 Ligase and Contribute to Cyclin D1 Overexpression in Human Cancer. <i>Cancer Cell</i> , 2008, 14, 68-78.	16.8	135
136	T-type Ca ²⁺ channel expression in human esophageal carcinomas: A functional role in proliferation. <i>Cell Calcium</i> , 2008, 43, 49-58.	2.4	69
137	Electrospun Water-Soluble Carboxyethyl Chitosan/Poly(vinyl alcohol) Nanofibrous Membrane as Potential Wound Dressing for Skin Regeneration. <i>Biomacromolecules</i> , 2008, 9, 349-354.	5.4	430
138	T-type Ca ²⁺ Channel Expression in Human Esophageal Carcinomas: A Functional Role in Proliferation. <i>FASEB Journal</i> , 2007, 21, A538.	0.5	0
139	Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. <i>Cancer Biology and Therapy</i> , 2006, 5, 152-155.	3.4	27
140	Is there a role for T-type Ca ²⁺ channel in glioma cell proliferation?. <i>Cell Calcium</i> , 2005, 38, 593-595.	2.4	7
141	Conditional JAG1 Mutation Shows the Developing Heart Is More Sensitive Than Developing Liver to JAG1 Dosage. <i>American Journal of Human Genetics</i> , 2003, 72, 1065-1070.	6.2	55
142	An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. <i>Cancer Research</i> , 2003, 63, 7056-61.	0.9	190